GeneralConnection.com ➔ Dictionary
Dictionary Search

lutetium

Synonyms

Noun

1. lutecium

2. Lu, atomic number 71, metallic element, metal

Usage
Lutetium Lu 177 Vipivotide Tetraxetan Provides rPFS Benefit in mHSPC Regardless of Disease Volume or De Novo/Recurrent Status - OncLive
PSMAddition Trial of ADT, ARPI, and Lutetium-177 in Metastatic Hormone-Sensitive Prostate Cancer - Fred Saad - UroToday
Curium, Lantheus win patent dispute over lutetium-177 dotatate products - AuntMinnie
MURR makes NCA Lu-177 available worldwide - Show Me Mizzou
Lutetium Lu 177 Dotatate Radioequivalent Receives Tentative FDA Approval for SSTR+ GEP-NETs - OncLive
Adaptive Dosing of Lutetium PSMA Based on Imaging and PSA Response - Louise Emmett - UroToday
Lutetium Lu 177 Vipivotide Tetraxetan Triplet Shows Consistent rPFS Benefit Across Disease Volume and mHSPC Status Subgroups - OncLive
The PLUDO Study: Comparing First-Line Lutetium vs Docetaxel in Chemo-Naive Metastatic Prostate Cancer - Kim Chi - UroToday
Lutetium Lu 177 Vipivotide Tetraxetan Plus ADT and an ARPI Maintains QOL in mHSPC - OncLive
APCCC 2026: How to Optimally Select Patients for Lutetium-PSMA Radioligand Therapy? - UroToday
APCCC 2026: How to Make Best Use of Lutetium-PSMA Radioligand Therapy? - UroToday
Lutetium Lu 177 Vipivotide Tetraxetan Remains Effective After Sipuleucel-T in mCRPC - OncLive
Real-World Analysis of Lutetium-177 in mCRPC by Taxane Treatment Sequence - Micah Ostrowski - UroToday
Lutetium Lu 177 Vipivotide Tetraxetan Plus ADT/ARPI Improves Frequency, Depth of PSA Responses in PSMA+ mHSPC - OncLive
Lutetium Lu 177 Dotatate Shows Promise in Advanced Intracranial Meningioma - OncLive
Lutetium-177 Rosopatamab Tetraxetan Plus SOC Meets Primary Safety End Point in PSMA+ mCRPC - OncLive
Lutetium-177 PSMA-617 Therapy Across the Prostate Cancer Spectrum: Mechanism, Formulation, and Future Directions - Phillip Koo - UroToday
PSMAddition Data Support Integration of Lutetium Lu 177 Vipivotide Tetraxetan into mHSPC Management - OncLive
Lutetium-177-PSMA-617 in First-Line mHSPC and Its Impact on PSA Depth, Undetectable Rates, and Time to Progression - Fred Saad - UroToday
Lutetium Lu 177 Vipivotide Tetraxetan Plus ARPI/ADT Yields Superior PFS in PSMA+ mHSPC - OncLive
Lutetium-177 PSMA-617 Delays Progression in Early-Stage Prostate Cancer - Targeted Oncology
PSMACare: Early Lutetium RLT in High-Risk nmCRPC - Fred Saad - UroToday
Integrating Lutetium-177-PSMA-617: Sequencing, Combinations, and Safety in Taxane-Naïve mCRPC - Michael Morris - UroToday
Lutetium Lu 177 Dotatate Yields Partial Responses in Metastatic Bronchopulmonary Neuroendocrine Tumors - OncLive
Dr Kurz on the Efficacy and Safety of Lutetium Lu 177 Dotatate in Advanced Intracranial Meningioma - OncLive
Lutetium 177 Market Size, Share and Trends Report 2025 to 2034 - Insightace Analytic
LUNAR Trial: Neoadjuvant Lutetium-PSMA Plus SBRT Evaluated in Oligometastatic Prostate Cancer - Amar Kishan & Jeremie Calais - UroToday
Dr Chi on Potential Prognostic Markers for Lutetium Lu 177 Vipivotide Tetraxetan in PSMA+ mCRPC - OncLive
Safety and Dosing of Lutetium-PSMA in the Pre-Chemotherapy PSMAfore Trial - Oliver Sartor - UroToday
Lu 177 Plus Immunotherapy Displays Responses in Prostate Cancer - CancerNetwork
FDA approves earlier use of lutetium Lu 177 vipivotide tetraxetan for patients with PSMA-positive metastatic castration-resistant prostate cancer - Mayo Clinic
Phase II LUNAR Trial Results: Adding Lutetium PSMA to SBRT for Oligorecurrent Prostate Cancer - Amar Kishan - UroToday
The isotope’s journey - Show Me Mizzou
Lutetium Lu 177 Vipivotide Tetraxetan Enables Some Patients with mCRPC to Avoid Chemotherapy - OncLive
Exploration of bridge length variations on the optical and photodynamic features of the zinc(II) and lutetium(III) phthalocyanines - ScienceDirect.com
Lutetium-177 PSMA-617 Plus ADT and ARPI Improves Progression-Free Survival in PSMAddition Trial - Pharmacy Times
Interim PSMAddition Analysis Shows Lutetium PSMA-617 Improves rPFS in mHSPC - Scott Tagawa - UroToday
Prior Radium-223 Does Not Affect Cancer-Control Outcomes With Lutetium-177-PSMA in mCRPC - Cancer Therapy Advisor
Access to Lu177-PSMA for Prostate Cancer: From Clinical Trials to the Real World - ASCO Daily News
Dr Tagawa on the Rationale for Evaluating Lutetium Lu 177 Vipivotide Tetraxetan Plus ARPI and ADT in PSMA+ mHSPC - OncLive
Lutetium-177 With RT Prolongs Survival in Prostate Cancer - Medscape
Dr Tagawa on Factors for Lutetium Lu 177 Vipivotide Tetraxetan Use Before Docetaxel in mCRPC - OncLive
Implementing Lutetium-PSMA — From Trial Design to Operations - Oliver Sartor - UroToday
Dr Tagawa on the PSMAddition Trial of Lutetium Lu 177 Vipivotide Tetraxetan Plus ARPI and ADT in PSMA+ mHSPC - OncLive
Lutetium and hafnium tell the story of liquid water on asteroid Ryugu - Physics Today
Raul Tirinescu: Timing of Lutetium-177 PSMA Therapy in Prostate Cancer Treatment - Oncodaily
UCLA Health launches novel clinical trial for recurrent prostate cancer - UCLA Health
Affibody Signs Letter of Intent with SHINE Technologies for Supply of Lutetium-177 - Cision News
Kim Chi, MD, discusses the PR.21 study of lutetium vs docetaxel in mCRPC - Urology Times
Lu-177 PSMA-SPECT/CT predicts survival in mCRPC - AuntMinnie
First-Line [177Lu]Lu-PSMA-617 Therapy Without ADT, Chemotherapy, or Local Therapy for Metastatic Hormone-Sensitive Prostate Cancer - Journal of Nuclear Medicine
EVOLUTION Trial: Ipilimumab/Nivolumab Plus Lutetium-PSMA Improves mCRPC Outcomes - Shahneen Sandhu - UroToday
Radiopharma Sector Races To Secure Actinium-225 Supply as Pipelines Expand - BioSpace
Telix advances PSMA radiotherapy challenger to Pluvicto - BioWorld News
Lutetium-Based Nanoprobes for Radiosensitization with Immune Microenvironment Remodeling and NIR-II Fluorescence Imaging-Guided Surgery in Colorectal Cancer - Wiley & Sons
Korea Localizes Production of Lutetium-177, a Radioisotope with a ₩2 Trillion Global Market - 동아사이언스
Radioligand Therapy (RLT) Market worth $10.91 billion by 2035 - MarketsandMarkets
LSR: Dysprosium, terbium and lutetium in xenotime... huh? The market liked it. - Next Investors
Lu-PSMA Therapy in Prostate Cancer: A Systematic Review and Meta-analysis - Journal of Nuclear Medicine
Dysprosium, cerium, indium, yttrium, and lutetium as emerging contributors to oxidative stress in polycystic ovary syndrome - Nature
ASCO 2025: How to Get Lutetium-177 PSMA to Those That Will Most Benefit? - UroToday
ctDNA Biomarkers in TheraP Trial: Cabazitaxel vs Lutetium-PSMA Comparison - Alexander Wyatt - UroToday
Adding lutetium (177Lu) vipivotide tetraxetan to SOC improves rPFS in mHSPC - Urology Times
SUVmean on PSMA PET Predicts Lutetium-PSMA Therapy Success in mCRPC - Koichiro Kimura - UroToday
Lu]Lu-DOTATATE safety: a comprehensive disproportionality analysis from the WHO pharmacovigilance database - Nature
New theranostic pairing shows promise for upper gastrointestinal tumors - AuntMinnie
Personalizing Lutetium-177 Dosing: The FLEX-MRT Trial Approach - Adrien Holzgreve - UroToday
Lutetium-177–PSMA-617 for Metastatic Castration-Resistant Prostate Cancer - The New England Journal of Medicine
Lutetium-177–PSMA-617 or cabazitaxel in metastatic prostate cancer: circulating tumor DNA analysis of the randomized phase 2 TheraP trial - Nature
Beyond Lutetium PSMA: Exploring Terbium-161 for Treatment-Resistant Prostate Cancer "Presentation" - Michael Hofman - UroToday
Cancer patients told treatment no longer available at public hospitals - ABC News & Headlines – Australian Broadcasting Corporation
Variability in Clinical Practice of Lutetium-177 Therapies - Journal of Nuclear Medicine
Lutetium Lu 177 Vipivotide Tetraxetan Generates rPFS Improvement in PSMA+ mHSPC - OncLive
FDA Expands Indication for Lutetium Lu 177 Vipivotide Tetraxetan in mCRPC - OncLive
177Lu-DOTATATE prolongs progression-free survival in previously treated advanced GEP-NETs - ESMO Daily Reporter
Meta-analysis shows PFS benefit with 177Lu-PSMA-617 in mCRPC - Urology Times
SK Biopharm in-licenses WT-7695 radiopharmaceutical targeting CA9, plans lutetium therapy and gallium diagnostic - CHOSUNBIZ - Chosunbiz
Lutetium-177 shows significant rPFS benefit for metastatic prostate cancer - Mayo Clinic
A scalable protocol for the radiosynthesis of clinical grade lutetium-177-labeled theranostic agents - Nature
Prior Abiraterone Strengthens Outcomes With Lutetium Lu 177 Vipivotide Tetraxetan in mCRPC - OncLive
Feasibility of Multi-Peak Acquisition Strategies for Rapid Quantitative Lutetium-177 SPECT/CT - Journal of Nuclear Medicine
Terbium-161 vs Lutetium-177: Comparing Next-Gen Radioligands for Prostate Cancer - Michael Hofman - UroToday
Actinium-PSMA J591 After Prior Lutetium Therapy in Metastatic Prostate Cancer - Scott Tagawa - UroToday
Overall Survival With Lutetium 177 May Be Impacted by Subsequent Therapies, Prognostic Risk Groups in mCRPC - CancerNetwork
Microscopic theory of colour in lutetium hydride - Nature
FDA Receives 505(b)(2) NDA Seeking Approval for Lutetium Lu 177 Dotatate - Targeted Oncology
Radioligand Therapy Market Size, Share, Growth, Analysis, 2034 - Straits Research
ESMO backs lutetium therapy in updated prostate cancer guideline - the limbic
Optimizing Lutetium-PSMA Dosing in High-Volume Disease and Special Situations - Louise Emmett - UroToday
Advancements in Lutetium-PSMA Therapy for Prostate Cancer: Clinical Trials and Future Directions - Ken Herrmann - UroToday
Worthing prostate cancer patient receives cutting-edge therapy - BBC
Lutetium PSMA Beyond Six Cycles Extended Treatment and Re-Challenge Approaches "Presentation" - Matthias Eiber - UroToday
Possible Superconductivity Transition in Nitrogen-Doped Lutetium Hydride Observed at Megabar Pressure - Wiley & Sons
Effectiveness of PSMA-Lutetium for Prostate Cancer Liver Metastases - Daniel Childs - UroToday
Blue Earth Therapeutics Advances Clinical Development of Lutetium (177Lu) rhPSMA-10.1 Injection with Promising Phase 1 Data - PR Newswire
Theranostics in nmCRPC: From PSMA PET Imaging to Lutetium-177 Therapy - Sherief Gamie - UroToday
Lutetium Lu 177 Timing Study: Early vs. Late Post-Chemo PSA Response - Eman Ahmed & Jack Andrews - UroToday
Phase II ENZA-p Trial Explores Effect of Lutetium PSMA With Enzalutamide - Louise Emmett - UroToday
Rapid xSPECT/CT Post Treatment Whole Body Imaging Following Lutetium DOTATATE and Lutetium PSMA Therapies - Journal of Nuclear Medicine
First-Line Lutetium Lu 177 Dotatate Plus Octreotide Improves PFS in Advanced Gastroenteropancreatic NETs - OncLive
Foreign Language Equivalents
Foreign Language Equivalents of 'lutetium'
Language Equivalent   Language Equivalent
French    Spanish
Misspellings - Typos
luutetium,   ltuetium,   lutetiium,   lutetiuum,   luretium,   luettium,   lutettium,   luteyium,   lutetiun,   kutetium,   lutrtium,   lutetiym,   lutetoum,   lutetum,   lutetuim,   luttium,   lutetiim,   luteium,   ltetium,   ultetium,   lytetium,   luteetium,   luyetium,   lutetiu,   luttetium,   utetium,   litetium,   lutetiu,,   lutwtium,   ;utetium,   luterium,   luteitum,   lutetimu,   luetium,   llutetium,   lutetuum,   lutetim,   lutetiumm,   lutteium
Words Starting with Letter - 'A'
a a battery a billion
a bit a bit much a capella singing
a cappella singing a couple of a few
a fortiori a good deal a great deal
a horizon a hundred a hundred and one
a hundred thousand a hundred times a kempis
a la carte a la mode a level
a little a lot a million
Go to Page 1              Go to Page 2 »   
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z